Literature DB >> 2941589

In vivo activated peripheral T cells in autoimmune disease.

A Raedler, G Bredow, W Kirch, H G Thiele, H Greten.   

Abstract

Starting from the observation, if that in patients suffering from inflammatory bowel diseases elevated numbers of activated peripheral immunocytes can be detected in correlation to the activity of the disease, subpopulations of lymphocytes in immune-mediated disorders were analyzed for the expression of activation associated antigens. It was found that in patients with immunovasculitis, sarcoidosis, M. Behçet, multiple sclerosis, antibody-mediated hemophilia, SLE,--but not in those with scleroderma--, increased numbers of activated immunocytes could be detected during acute exacerbation, whereas, in remission, the population of activated immunocytes was in the upper normal range. Analyses of phenotypes revealed that the majority of activated immunocytes are T cells. However, a variable minority of cells bear B cell associated determinants. As is the case in total peripheral T cells, the T4 to T8 ratio was in a normal range. Only in Behçet disease and immunovasculitis was the ratio of activated T4 positive to activated T8 positive lymphocytes found to be decreased. In contrast to T cells in patients with inflammatory bowel disease, the majority of activated T cells in the autoimmune disorders under study does not express Fc alpha-receptors. In Behçet disease and immunovasculitis moreover, the incidence of activated Leu 7 positive (= natural killer) cells is low compared to T cells from patients with Crohn's disease or ulcerative colitis. These experiments lead to the conclusion that the assessment of activated immunocytes may serve as a parameter in the evaluation of the clinical activity of autoimmune diseases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941589

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  6 in total

Review 1.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Phenotype and functional properties of Vicia villosa agglutinin (VVA) binding T cells in patients with Crohn's disease: detection of contrasuppressor activity in patients lacking extra-intestinal manifestations, abscesses and fistulas.

Authors:  A Raedler; H J Lenz; K Sandgren; A de Weerth; S Enversen; S Schreiber; H G Thiele; H Greten
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

3.  Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet's disease.

Authors:  K Hamzaoui; K Ayed; A Slim; M Hamza; J Touraine
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

Review 4.  Dendritic cells and multiple sclerosis: disease, tolerance and therapy.

Authors:  Mohammad G Mohammad; Masoud Hassanpour; Vicky W W Tsai; Hui Li; Marc J Ruitenberg; David W Booth; Jordi Serrats; Prue H Hart; Geoffrey P Symonds; Paul E Sawchenko; Samuel N Breit; David A Brown
Journal:  Int J Mol Sci       Date:  2012-12-27       Impact factor: 5.923

5.  Levels of soluble Fas/APO-1 in patients with Behçet's disease.

Authors:  K Hamzaoui; A Hamzaoui; L Zakraoui; A Chabbou
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

6.  Soluble interleukin-2 receptors in ulcerative colitis.

Authors:  O H Nielsen; J Brynskov
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.